drugset / Trial / NCT07207408
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Phase 2
Recruiting
148 enrolled
Dynavax Technologies Corporation
United States Department of Defense · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Timeline
- Start
- 2025-09-11
- Primary completion
- 2027-01-29
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rF1V-1018 | Vaccine | — | — |